The company expects a fourth straight year of stagnant product revenue -- and declining gross margin, to boot. Those are noteworthy red flags for investors.
News & Analysis: Codexis
The enzyme engineering company reported disappointing full-year 2019 operating results.
The enzyme leader announced a new and improved technology licensing deal with pharma giant Merck.
The enzyme and protein manufacturer reported second-quarter 2018 earnings.
Shares plunged after the company announced the pricing details of a common stock offering.
The small cap biotech company provided disappointing guidance for 2018.